Jennifer Batson
Development of potent, selective SRPK1 inhibitors as potential topical therapeutics for neovascular eye disease
Batson, Jennifer; Toop, Hamish D.; Redondo, Clara; Babaei-Jadidi, Roya; Chaikaud, Apirat; Wearmouth, Stephen F.; Gibbons, Brian; Allen, Claire; Tallant, Cynthia; Zhang, Jingxue; Du, Chunyun; Hancox, Jules C.; Hawtrey, Tom; Da Rocha, Joana; Griffith, Renate; Knapp, Stefan; Bates, David O.; Morris, Jonathan C.
Authors
Hamish D. Toop
Clara Redondo
ROYA BABAEI-JADIDI Roya.Babaei-jadidi@nottingham.ac.uk
Research Fellow
Apirat Chaikaud
Stephen F. Wearmouth
Brian Gibbons
Claire Allen
Cynthia Tallant
Jingxue Zhang
Chunyun Du
Jules C. Hancox
Tom Hawtrey
Joana Da Rocha
Renate Griffith
Stefan Knapp
DAVID BATES David.Bates@nottingham.ac.uk
Professor of Oncology
Jonathan C. Morris
Abstract
Serine/arginine-protein kinase 1 (SRPK1) regulates alternative splicing of VEGF-A to pro-angiogenic isoforms and SRPK1 inhibition can restore the balance of pro/antiangiogenic isoforms to normal physiological levels. The lack of potency and selectivity of available compounds has limited development of SRPK1 inhibitors, with the control of alternative splicing by splicing factor-specific kinases yet to be translated. We present here compounds that occupy a binding pocket created by the unique helical insert of SRPK1, and trigger a backbone flip in the hinge region, that results in potent (<10 nM) and selective inhibition of SRPK1 kinase activity. Treatment with these inhibitors inhibited SRPK1 activity and phosphorylation of serine/arginine splicing factor 1 (SRSF1), resulting in alternative splicing of VEGF-A from pro-angiogenic to antiangiogenic isoforms. This property resulted in potent inhibition of blood vessel growth in models of choroidal angiogenesis in vivo. This work identifies tool compounds for splice isoform selective targeting of pro-angiogenic VEGF, which may lead to new therapeutic strategies for a diversity of diseases where dysfunctional splicing drives disease development.
Citation
Batson, J., Toop, H. D., Redondo, C., Babaei-Jadidi, R., Chaikaud, A., Wearmouth, S. F., Gibbons, B., Allen, C., Tallant, C., Zhang, J., Du, C., Hancox, J. C., Hawtrey, T., Da Rocha, J., Griffith, R., Knapp, S., Bates, D. O., & Morris, J. C. (2017). Development of potent, selective SRPK1 inhibitors as potential topical therapeutics for neovascular eye disease. ACS Chemical Biology, 12(3), 825-832. https://doi.org/10.1021/acschembio.6b01048
Journal Article Type | Article |
---|---|
Acceptance Date | Jan 30, 2017 |
Online Publication Date | Feb 6, 2017 |
Publication Date | Mar 17, 2017 |
Deposit Date | Jul 11, 2017 |
Publicly Available Date | Jul 11, 2017 |
Journal | ACS Chemical Biology |
Print ISSN | 1554-8929 |
Electronic ISSN | 1554-8937 |
Publisher | American Chemical Society |
Peer Reviewed | Peer Reviewed |
Volume | 12 |
Issue | 3 |
Pages | 825-832 |
DOI | https://doi.org/10.1021/acschembio.6b01048 |
Public URL | https://nottingham-repository.worktribe.com/output/838564 |
Publisher URL | http://pubs.acs.org/doi/abs/10.1021/acschembio.6b01048 |
Contract Date | Jul 11, 2017 |
Files
acschembio.6b01048.pdf
(5.6 Mb)
PDF
Copyright Statement
Copyright information regarding this work can be found at the following address: http://eprints.nottingham.ac.uk/end_user_agreement.pdf
You might also like
Downloadable Citations
About Repository@Nottingham
Administrator e-mail: discovery-access-systems@nottingham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search